Total microfluidic platform strategy for liquid biopsy

2020 ◽  
pp. 1-25
Author(s):  
Sehyun Shin
Keyword(s):  
Liquid Biopsy ◽  
Residual Disease ◽  
Future Research ◽  
Microfluidic Platforms ◽  
Liquid Biopsies ◽  
Related Area ◽  
Detailed Review ◽  
Non Invasive ◽  
Clinical Benefits ◽  
Minimal Residual

A liquid biopsy is a simple and non-invasive biopsy that examines a range of information about a tumor through a simple blood sample. Due to its non-invasive nature, liquid biopsy has many outstanding clinical benefits, including repetitive sampling and examination, representation of whole mutations, observation of minimal residual disease etc. However, liquid biopsy requires various processes such as sample preparation, amplification, and target detection. These processes can be integrated onto microfluidic platforms, which may provide a sample-to-answer system. The present review provides a brief overview of liquid biopsies, a detailed review of the technologies in each process, and prospective concluding remarks. Through this review, one can have a basic but cross-disciplinary understanding of liquid biopsy, as well as knowledge of new starting points for future research in each related area.

scholarly journals Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2101
Author(s):  
Ângela Carvalho ◽  
Gabriela Ferreira ◽  
Duarte Seixas ◽  
Catarina Guimarães-Teixeira ◽  
Rui Henrique ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Liquid Biopsy ◽  
Residual Disease ◽  
Lab On A Chip ◽  
Microfluidic Devices ◽  
Early Recurrence ◽  
Circulating Tumor Dna ◽  
Clinical Validation ◽  
Liquid Biopsies ◽  
Lung Cancer Patients

Despite the intensive efforts dedicated to cancer diagnosis and treatment, lung cancer (LCa) remains the leading cause of cancer-related mortality, worldwide. The poor survival rate among lung cancer patients commonly results from diagnosis at late-stage, limitations in characterizing tumor heterogeneity and the lack of non-invasive tools for detection of residual disease and early recurrence. Henceforth, research on liquid biopsies has been increasingly devoted to overcoming these major limitations and improving management of LCa patients. Liquid biopsy is an emerging field that has evolved significantly in recent years due its minimally invasive nature and potential to assess various disease biomarkers. Several strategies for characterization of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have been developed. With the aim of standardizing diagnostic and follow-up practices, microfluidic devices have been introduced to improve biomarkers isolation efficiency and specificity. Nonetheless, implementation of lab-on-a-chip platforms in clinical practice may face some challenges, considering its recent application to liquid biopsies. In this review, recent advances and strategies for the use of liquid biopsies in LCa management are discussed, focusing on high-throughput microfluidic devices applied for CTCs and ctDNA isolation and detection, current clinical validation studies and potential clinical utility.

scholarly journals Rationale for Early Detection of EWSR1 Translocation-Associated Sarcoma Biomarkers in Liquid Biopsy

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 824
Author(s):  
Felix I. L. Clanchy
Keyword(s):  
Early Detection ◽  
Liquid Biopsy ◽  
Residual Disease ◽  
Surgical Excision ◽  
Molecular Techniques ◽  
Rt Pcr ◽  
Liquid Biopsies ◽  
Societal Burden ◽  
Recent Developments ◽  
Mesenchymal Tumours

Sarcomas are mesenchymal tumours that often arise and develop as a result of chromosomal translocations, and for several forms of sarcoma the EWSR1 gene is a frequent translocation partner. Sarcomas are a rare form of malignancy, which arguably have a proportionally greater societal burden that their prevalence would suggest, as they are more common in young people, with survivors prone to lifelong disability. For most forms of sarcoma, histological diagnosis is confirmed by molecular techniques such as FISH or RT-PCR. Surveillance after surgical excision, or ablation by radiation or chemotherapy, has remained relatively unchanged for decades, but recent developments in molecular biology have accelerated the progress towards routine analysis of liquid biopsies of peripheral blood. The potential to detect evidence of residual disease or metastasis in the blood has been demonstrated by several groups but remains unrealized as a routine diagnostic for relapse during remission, for disease monitoring during treatment, and for the detection of occult, residual disease at the end of therapy. An update is provided on research relevant to the improvement of the early detection of relapse in sarcomas with EWSR1-associated translocations, in the contexts of biology, diagnosis, and liquid biopsy.

scholarly journals The Translational Status of Cancer Liquid Biopsies

2019 ◽  
Author(s):  
Sinisa Bratulic ◽  
Francesco Gatto ◽  
Jens Nielsen
Keyword(s):  
Treatment Outcomes ◽  
Liquid Biopsy ◽  
Tumor Tissue ◽  
Body Fluids ◽  
Precision Oncology ◽  
Liquid Biopsies ◽  
Non Invasive ◽  
Biomarker Research ◽  
Successes And Challenges

Abstract Precision oncology aims to tailor clinical decisions specifically to patients with the objective of improving treatment outcomes. This can be achieved by leveraging omics information for accurate molecular characterization of tumors. Tumor tissue biopsies are currently the main source of information for molecular profiling. However, biopsies are invasive and limited in resolving spatiotemporal heterogeneity in tumor tissues. Alternative non-invasive liquid biopsies can exploit patient’s body fluids to access multiple layers of tumor-specific biological information (genomes, epigenomes, transcriptomes, proteomes, metabolomes, circulating tumor cells, and exosomes). Analysis and integration of these large and diverse datasets using statistical and machine learning approaches can yield important insights into tumor biology and lead to discovery of new diagnostic, predictive, and prognostic biomarkers. Translation of these new diagnostic tools into standard clinical practice could transform oncology, as demonstrated by a number of liquid biopsy assays already entering clinical use. In this review, we highlight successes and challenges facing the rapidly evolving field of cancer biomarker research. Lay Summary Precision oncology aims to tailor clinical decisions specifically to patients with the objective of improving treatment outcomes. The discovery of biomarkers for precision oncology has been accelerated by high-throughput experimental and computational methods, which can inform fine-grained characterization of tumors for clinical decision-making. Moreover, advances in the liquid biopsy field allow non-invasive sampling of patient’s body fluids with the aim of analyzing circulating biomarkers, obviating the need for invasive tumor tissue biopsies. In this review, we highlight successes and challenges facing the rapidly evolving field of liquid biopsy cancer biomarker research.

Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e19092-e19092 ◽  
Author(s):  
James Michael Randall ◽  
Mark G. Erlander ◽  
Cecile Rose T. Vibat ◽  
Saege Hancock ◽  
Vlada Melnikova ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Treatment Response ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Circulating Tumor Dna ◽  
Invasive Monitoring ◽  
Non Invasive ◽  
Tumor Dna ◽  
Minimal Residual

scholarly journals 91P Liquid biopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer

2021 ◽  
Vol 32 ◽  
pp. S395-S396
Author(s):  
M.A. Gouda ◽  
M.J. Overman ◽  
H.J. Huang ◽  
J. Thomas ◽  
N.A. Dasari ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Minimal Residual Disease ◽  
Liquid Biopsy ◽  
Residual Disease ◽  
Stage Iv ◽  
Stage Iv Colorectal Cancer ◽  
Minimal Residual

Liquid biopsy: a new diagnostic modality

2020 ◽  
pp. 3-8
Author(s):  
Pranab Dey
Keyword(s):  
Liquid Biopsy ◽  
Residual Disease ◽  
Chemotherapeutic Agents ◽  
Specific Gene ◽  
Clinical Use ◽  
Circulating Tumour Cells ◽  
Diagnostic Modality ◽  
Minimal Residual ◽  
Selection Of ◽  
Sophisticated Technology

The liquid biopsy is the most promising technology in the modern days. It plays a significant role in the diagnosis, management and finding out the minimal residual disease in carcinoma. There are three components of the liquid biopsy: circulating tumour cells (CTC), cell-free DNA (cf-DNA), and exosomes. These components carry vital information, and with the help of sophisticated technology, one can extract a large amount of data from them. The detection of the tumour-specific gene mutation in the CTC or cf-DNA may guide the clinicians about the selection of the appropriate chemotherapeutic agents. The liquid biopsy is still not applied for routine clinical use, and more research is needed in this field. In this review, the techniques and applications of liquid biopsy have been discussed.

Sign in / Sign up

Export Citation Format

Share Document